24 HOUR WU ALLOCATION
| Research | Percent |
|---|---|
|
ANTIBODY DYNAMICS |
73.91% |
|
IL 2 RECEPTOR DYNAMICS |
26.09% |
7 DAY WU ALLOCATION
| Research | Percent |
|---|---|
|
ANTIBODY DYNAMICS |
33.83% |
|
IL 2 RECEPTOR DYNAMICS |
15.42% |
|
ANTIBODY DYNAMICS SIMULATION |
14.93% |
|
ENZYME DYNAMICS |
11.94% |
|
IL 2 FORCE FIELD BENCHMARKING |
7.46% |
|
ANTIBODY AFFINITY MATURATION |
7.46% |
|
ALZHEIMERS |
6.47% |
|
IL 2 DYNAMICS SIMULATIONS |
2.49% |
12 WEEK WU ALLOCATION
| Research | Percent |
|---|---|
|
CANCER |
28.34% |
|
ALZHEIMERS |
10.25% |
|
IL 2 DYNAMICS SIMULATIONS |
10.08% |
|
IL 2 FORCE FIELD BENCHMARKING |
9.8% |
|
ANTIBODY DYNAMICS |
8.28% |
|
ANTIBODY DYNAMICS SIMULATION |
7.49% |
|
ANTIBODY AFFINITY MATURATION |
7.15% |
|
IL 2 RECEPTOR DYNAMICS |
5.14% |
|
IL2 RECEPTOR DYNAMICS |
4.11% |
|
ENZYME DYNAMICS |
3.49% |
|
IL 2 MOLECULAR DYNAMICS |
3% |
|
STP6 SUGAR TRANSPORT |
1.59% |
|
MEMBRANE TRANSPORT |
1% |
|
SUCROSE TRANSPORT PLANTS |
.21% |
|
PARKINSONS |
.07% |